公开(公告)号：US20220143102A1

公开(公告)日：2022-05-12

申请号：US17587685

申请日：2022-01-28

Applicant: ACADEMIA SINICA

Inventor： Che-Kun James SHEN ,  Yu-Chiau SHYU ,  Chun-Hao HUNG

IPC: A61K35/545 ,  A61P35/00 ,  C07K14/47 ,  C12N5/0735 ,  C12N5/0775 ,  C12N5/074 ,  C12N5/0789

Abstract: The invention found that first, the feasibility of transfer of tumor resistance and other healthy longevity characters through transplantation of bone marrow mononuclear cells (BMMNC) or hematopoietic stem cells (HSC)/hematopoietic stem and progenitor cells (HSPC) consisting of genetically engineered EKLF gene encoding the hematopoietic transcription factor EKLF. Secondly, the present invention demonstrates expression of EKLF in the long-term hematopoietic stem cells (LT-HSC), and thus EKLF as a target of regulation of hematopoiesis.

公开(公告)号：US20190282625A1

公开(公告)日：2019-09-19

申请号：US16333186

申请日：2017-09-13

Applicant: Che-Kun James SHEN ,  Yu-Chiau SHYU ,  Chun-Hao HUNG ,  Academia Sinica

Inventor： Che-Kun James SHEN ,  Yu-Chiau SHYU ,  Chun-Hao HUNG

IPC: A61K35/545 ,  C07K14/47 ,  A61P35/00 ,  C12N5/074 ,  C12N5/0735 ,  C12N5/0775

Abstract: The invention found that first, the feasibility of transfer of tumor resistance and other healthy longevity characters through transplantation of bone marrow mononuclear cells (BMMNC) or hematopoietic stem cells (HSC)/hematopoietic stem and progenitor cells (HSPC) consisting of genetically engineered EKLF gene encoding the hematopoietic transcription factor EKLF. Secondly, the present invention demonstrates expression of EKLF in the long-term hematopoietic stem cells (LT-HSC), and thus EKLF as a target of regulation of hematopoiesis.

公开(公告)号：US20170283477A1

公开(公告)日：2017-10-05

申请号：US15507650

申请日：2015-09-01

Applicant: ACADEMIA SINICA

Inventor： Che-Kun James SHEN ,  Yu-Chiau SHYU

IPC: C07K14/47 ,  A61K38/17 ,  A61K45/06 ,  A01K67/027

CPC classification number: C07K14/4702 ,  A01K67/0275 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2267/0331 ,  A61K38/1709 ,  A61K45/06 ,  C07K14/4703 ,  Y02A50/402

Abstract: The present invention includes a genetically-modified non-human animal model of longevity and increased health span, which is associated with reduced tumorigenesis and tumor metastasis, as well as related methods for increasing longevity and health span, reducing tumorigenesis and tumor metastasis, and identifying active agents that confer increased longevity or health span, or reduced tumorigenesis or tumor metastasis.